S&P 500   3,097.25 (+0.33%)
DOW   27,729.60 (+0.14%)
QQQ   201.92 (+0.48%)
CGC   19.42 (-4.38%)
BABA   186.85 (+0.07%)
GE   11.55 (+1.76%)
T   39.26 (-0.28%)
F   9.09 (+0.11%)
ACB   3.63 (+0.28%)
PRI   130.19 (+0.74%)
BAC   33.19 (+0.03%)
DIS   138.73 (+1.46%)
S&P 500   3,097.25 (+0.33%)
DOW   27,729.60 (+0.14%)
QQQ   201.92 (+0.48%)
CGC   19.42 (-4.38%)
BABA   186.85 (+0.07%)
GE   11.55 (+1.76%)
T   39.26 (-0.28%)
F   9.09 (+0.11%)
ACB   3.63 (+0.28%)
PRI   130.19 (+0.74%)
BAC   33.19 (+0.03%)
DIS   138.73 (+1.46%)
Log in

Aptinyx Stock Price, Forecast & Analysis (NASDAQ:APTX)

$3.32
+0.02 (+0.61 %)
(As of 11/12/2019 01:07 PM ET)
Today's Range
$3.25
Now: $3.32
$3.43
50-Day Range
$2.90
MA: $3.28
$3.89
52-Week Range
$2.61
Now: $3.32
$27.20
Volume1,173 shs
Average Volume93,270 shs
Market Capitalization$111.42 million
P/E RatioN/A
Dividend YieldN/A
Beta0.01
Aptinyx Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. It is developing NYX-2925 that is in Phase II clinical trial for the treatment of painful diabetic peripheral neuropathy, as well as in Phase II exploratory clinical trial for fibromyalgia; and NYX-783, an NMDAr receptor that is in Phase I clinical trial for the treatment of post-traumatic stress disorder. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:APTX
CUSIPN/A
CIKN/A
Phone847-871-0377

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$6.57 million
Book Value$4.46 per share

Profitability

Net Income$-53,280,000.00
Net Margins-1,504.24%

Miscellaneous

EmployeesN/A
Market Cap$111.42 million
Next Earnings Date11/12/2019 (Confirmed)
OptionableNot Optionable

Receive APTX News and Ratings via Email

Sign-up to receive the latest news and ratings for APTX and its competitors with MarketBeat's FREE daily newsletter.


Aptinyx (NASDAQ:APTX) Frequently Asked Questions

What is Aptinyx's stock symbol?

Aptinyx trades on the NASDAQ under the ticker symbol "APTX."

How were Aptinyx's earnings last quarter?

Aptinyx Inc (NASDAQ:APTX) announced its quarterly earnings data on Monday, August, 12th. The company reported ($0.36) earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.52) by $0.16. The firm had revenue of $0.93 million for the quarter, compared to analyst estimates of $0.95 million. Aptinyx had a negative return on equity of 40.01% and a negative net margin of 1,504.24%. View Aptinyx's Earnings History.

When is Aptinyx's next earnings date?

Aptinyx is scheduled to release their next quarterly earnings announcement on Tuesday, November 12th 2019. View Earnings Estimates for Aptinyx.

What price target have analysts set for APTX?

7 Wall Street analysts have issued 12 month target prices for Aptinyx's stock. Their forecasts range from $7.00 to $22.00. On average, they anticipate Aptinyx's stock price to reach $13.17 in the next year. This suggests a possible upside of 296.6% from the stock's current price. View Analyst Price Targets for Aptinyx.

What is the consensus analysts' recommendation for Aptinyx?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aptinyx in the last year. There are currently 1 sell rating and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Aptinyx.

What are Wall Street analysts saying about Aptinyx stock?

Here are some recent quotes from research analysts about Aptinyx stock:
  • 1. According to Zacks Investment Research, "Aptinyx Inc. is a bio-pharmaceutical company. It focuses on discovery, development, and commercialization of novel, proprietary and synthetic small molecules for the treatment of brain and nervous system disorders. The company's product pipeline consists of NYX-2925, NYX-783 and NYX-458 which are in clinical stage. Aptinyx Inc. is based in IL, United States. " (11/8/2019)
  • 2. Cantor Fitzgerald analysts commented, "We reiterate our OW rating and 12-month PT of $12 on APTX. With an initial focus on large indications within chronic pain, there are multiple nervous system disorder opptys for the company’s candidates that have a better safety/tolerability profile relative to historical NMDAr-based treatments like ketamine. Data from pre-clinical models look promising, and important PoC trial data should emerge this year. Valuation Summary We use a discounted NPV revenue calculation that yields ~$10 for NYX-2925 in DPN and ~$2 for pipeline placeholder ($75M total NPV) in fibromyalgia." (4/30/2019)

Has Aptinyx been receiving favorable news coverage?

Media coverage about APTX stock has trended very negative on Tuesday, InfoTrie Sentiment Analysis reports. The research group rates the sentiment of news coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Aptinyx earned a coverage optimism score of -3.2 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an effect on the company's share price in the near future. View News Stories for Aptinyx.

Are investors shorting Aptinyx?

Aptinyx saw a decline in short interest in September. As of September 30th, there was short interest totalling 586,000 shares, a decline of 7.0% from the August 30th total of 630,300 shares. Based on an average trading volume of 133,000 shares, the short-interest ratio is presently 4.4 days. Currently, 4.3% of the shares of the stock are sold short. View Aptinyx's Current Options Chain.

Who are some of Aptinyx's key competitors?

What other stocks do shareholders of Aptinyx own?

Who are Aptinyx's key executives?

Aptinyx's management team includes the folowing people:
  • Dr. Norbert G. Riedel, Pres, CEO & Director (Age 61)
  • Dr. Joseph R. Moskal Ph.D., Chief Scientific Officer (Age 68)
  • Dr. Torsten Meldgaard Madsen, Chief Medical Officer (Age 51)
  • Mr. Ashish Khanna, CFO & Chief Bus. Officer (Age 43)
  • Ms. Betty Y. Jang, VP of Legal Affairs (Age 50)

When did Aptinyx IPO?

(APTX) raised $77 million in an IPO on Thursday, June 21st 2018. The company issued 5,300,000 shares at a price of $14.00-$15.00 per share. J.P. Morgan, Cowen, Leerink Partners and BMO Capital Markets acted as the underwriters for the IPO.

Who are Aptinyx's major shareholders?

Aptinyx's stock is owned by many different of retail and institutional investors. Top institutional shareholders include Russell Investments Group Ltd. (0.22%) and Tower Research Capital LLC TRC (0.06%). Company insiders that own Aptinyx stock include Adam Koppel, Adams Street Partners Llc, Andrew Kidd, Ashish Khanna, Henry O Gosebruch, Norbert G Riedel, Robert J Hombach and Torsten M Madsen. View Institutional Ownership Trends for Aptinyx.

Which institutional investors are buying Aptinyx stock?

APTX stock was acquired by a variety of institutional investors in the last quarter, including Russell Investments Group Ltd. and Tower Research Capital LLC TRC . Company insiders that have bought Aptinyx stock in the last two years include Adam Koppel, Adams Street Partners Llc, Andrew Kidd, Ashish Khanna, Henry O Gosebruch, Norbert G Riedel, Robert J Hombach and Torsten M Madsen. View Insider Buying and Selling for Aptinyx.

How do I buy shares of Aptinyx?

Shares of APTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Aptinyx's stock price today?

One share of APTX stock can currently be purchased for approximately $3.32.

How big of a company is Aptinyx?

Aptinyx has a market capitalization of $111.42 million and generates $6.57 million in revenue each year. The company earns $-53,280,000.00 in net income (profit) each year or ($2.64) on an earnings per share basis. View Additional Information About Aptinyx.

What is Aptinyx's official website?

The official website for Aptinyx is http://www.aptinyx.com/.

How can I contact Aptinyx?

Aptinyx's mailing address is 1801 MAPLE AVENUE SUITE 4300, EVANSTON IL, 60201. The company can be reached via phone at 847-871-0377 or via email at [email protected]


MarketBeat Community Rating for Aptinyx (NASDAQ APTX)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  79 (Vote Outperform)
Underperform Votes:  80 (Vote Underperform)
Total Votes:  159
MarketBeat's community ratings are surveys of what our community members think about Aptinyx and other stocks. Vote "Outperform" if you believe APTX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe APTX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/12/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel